SCHEMBL5657977

SCHEMBL5657977

O=C(NCCOCCO)c1ccccc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
POLB P06746 1/20 0.58
ALDH1A1 P00352 3/20 0.54
HPGD P15428 2/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPT P10636 2/20 0.54
NPC1 O15118 2/20 0.54
NAAA Q02083 1/20 0.54
TSHR P16473 1/20 0.54
HTT P42858 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
NLRP1 Q9C000 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 4/20 0.49
ESRRG P62508 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
ALOX5 P09917 1/20 0.47
GAA P10253 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18235578 0.90 SMN1; SMN2 (0.59) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL1583804 0.88 MEN1 (0.62) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL1584943 0.86 MEN1 (0.57) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL12708259 0.85 MEN1 (0.56) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL1668940 0.83 ALDH1A1 (0.65) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL7678490 0.83 ALDH1A1 (0.59) ALDH1A1HPGDHSD17B10NPC1TSHR
SCHEMBL5655209 0.83 NPC1 (0.65) POLBHPGDNPC1SMN1; SMN2NAMPT
SCHEMBL13162943 0.83 NPC1 (0.59) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL5657924 0.83 HPGD (0.62) POLBALDH1A1HPGDMAPTTSHR
SCHEMBL13299189 0.83 SMN1; SMN2 (0.51) MEN1KMT2AALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US disclosed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP disclosed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO disclosed
US-20090324540-A1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2009-12-31 US disclosed
US-20090324540-A1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2009-12-31 US disclosed
US-7553872-B2 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2009-06-30 US disclosed
US-7553872-B2 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2009-06-30 US disclosed
US-7071214-B2 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2006-07-04 US disclosed
US-5466692-A Substituted pyridopyrimidines and antihypertensives AMERICAN HOME PRODUCTS CORPORATION (US) 1995-11-14 US disclosed
US-5458661-A MIXTURE OF HYDROCARBONS IN THE GASOLINE BOILING RANGE AND AN AROMATIC AMIDE CONTAINING PHENOL ALKOXYLATE SHELL OIL COMPANY (US) 1995-10-17 US disclosed
EP-0249473-B1 PHOTOGRAPHIC ACETANILIDE COUPLERS AND PHOTOGRAPHIC ELEMENTS CONTAINING THEM EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1992-08-12 EP disclosed
US-4758501-A Photographic acetanilide couplers and photographic elements containing them EASTMAN KODAK COMPANY (US) 1988-07-19 US disclosed
EP-0249473-A2 Photographic acetanilide couplers and photographic elements containing them EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1987-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324540-A1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS ABCB4, ABCB7, ALPP MEN1 2174/4885KMT2A 4430/4885POLB 1332/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 MEN1 3557/4885KMT2A 4752/4885POLB 2682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.